Corbus Pharmaceuticals Holdings (CRBP) Total Non-Current Liabilities (2016 - 2024)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Total Non-Current Liabilities of $13.5 million for Q4 2024, down 61.71% year-over-year from $35.1 million in Q1 2024, and down 1.62% quarter-over-quarter from $13.7 million in Q3 2024.
Corbus Pharmaceuticals Holdings (CRBP) Total Non-Current Liabilities (2016 - 2024) Analysis & Trends
Corbus Pharmaceuticals Holdings' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $13.5 million for Q4 2024.
- In Q4 2024, Total Non-Current Liabilities fell 61.71% year-over-year to $13.5 million; the TTM figure through Dec 2024 stood at $13.5 million (down 61.71% YoY), while the FY2024 annual figure was $13.5 million, down 61.71% from the prior year.
- Total Non-Current Liabilities for Q4 2024 stood at $13.5 million, down from $13.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $57.0 million in Q4 2020, with the low at $13.5 million in Q4 2024.
- The 5-year median for Total Non-Current Liabilities is $34.2 million (2023), against an average of $34.2 million.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities advanced 12.76% in 2023, then plunged 61.94% in 2024.
- Corbus Pharmaceuticals Holdings' Total Non-Current Liabilities stood at $57.0 million in 2020, then slumped by 32.3% to $38.6 million in 2021, then slipped by 13.73% to $33.3 million in 2022, then increased by 5.51% to $35.1 million in 2023, then tumbled by 61.71% to $13.5 million in 2024.
- Business Quant data shows CRBP's Total Non-Current Liabilities at $13.5 million in Q4 2024, $13.7 million in Q3 2024, and $26.4 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 9.32 Bn |
| 10 | Corbus Pharmaceuticals Holdings | 125.41 Mn | -37.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 13.45 Mn |
| Sep 30, 2024 | 13.67 Mn |
| Jun 30, 2024 | 26.44 Mn |
| Mar 31, 2024 | 28.78 Mn |
| Dec 31, 2023 | 35.13 Mn |
| Sep 30, 2023 | 35.93 Mn |
| Jun 30, 2023 | 34.18 Mn |
| Mar 31, 2023 | 32.66 Mn |
| Dec 31, 2022 | 33.30 Mn |
| Sep 30, 2022 | 31.86 Mn |
| Jun 30, 2022 | 32.57 Mn |
| Mar 31, 2022 | 34.50 Mn |
| Dec 31, 2021 | 38.60 Mn |
| Sep 30, 2021 | 41.82 Mn |
| Jun 30, 2021 | 43.05 Mn |
| Mar 31, 2021 | 47.83 Mn |
| Dec 31, 2020 | 57.02 Mn |
| Dec 31, 2017 | 9.19 Mn |
| Sep 30, 2017 | 6.44 Mn |
| Jun 30, 2017 | 6.97 Mn |